BioPharmSignal logoBioPharmSignal

Biotech News

Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026

Annovis Bio (ANVS)Annovis BioCompany update

Maria Maccecchini, PhD, CEO of Annovis, will join industry panel with pharma leaders and present company updates Maria Maccecchini, PhD, CEO of Annovis, will join industry panel with pharma leaders and present company updates

Related news

ANVSAnnovis Bio2026-10-22 12:00 EST

Annovis to Attend the CTAD 2026 with Three Presentations

ANVSAnnovis Bio2026-10-30 21:00 EST

Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE

MNOVMediciNova2026-10-06 10:00 EST

MediciNova to Participate in the Maxim Growth Summit

ECORelectroCore2026-11-05 13:00 EST

electroCore to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

MNOVMediciNova2026-09-08 10:00 EST

MediciNova to Participate in Two Investor Conferences in September

SUPNSupernus2026-09-02 20:30 EST

Supernus Pharmaceuticals to Participate in September Investor Conferences

View all latest news

Annovis Bio

Phase 3 Neurodegenerative Disease Company Annovis Bio is developing buntanetap, an oral candidate for Alzheimer’s disease and Parkinson’s disease. Through an RNA-targeting mechanism, buntanetap is designed to reduce translation of multiple neurotoxic proteins, including APP/amyloid beta, tau, alpha-synuclein, and TDP-43. Registrational...

Recent company news

ANVSAnnovis Bio2026-10-30 21:00 EST

Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE

ANVSAnnovis Bio2026-10-29 12:00 EST

Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026

ANVSAnnovis Bio2026-10-22 12:00 EST

Annovis to Attend the CTAD 2026 with Three Presentations

ANVSAnnovis Bio2026-09-23 12:00 EST

Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease

ANVSAnnovis Bio2026-08-25 12:00 EST

Annovis to Host Corporate Update Webinar on September 2, 2026

Stock data

Close
0.67 USD
Market cap
79.13M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States